Antes, G. (2003): [Funding for clinical research: A programme of the German Research Foundation (DFG). Editorial]. HTA-Newsletter 23: p. 1.

Breuer, J. and Reinsperger, I. and Piso, B. (2014): Acupuncture - areas of application, current evidence and proven indications. HTA-Projektbericht 78.

Busse, R. and Orvain, J. and Drummond, M. and Wild, C. (2001): Best practice in undertaking and reporting HTA. Working Group 4 Final Report. Projektbericht.

Busse, R. and Orvain, J. and Velasco-Garrido, M. and Perleth, M. and Drummond, M. and Wild, C. (2002): Best practice in undertaking and reporting health technology assessment. International Journal of Technology Assessment in Health Care 18 (02): pp. 361-422.

Erdos, J. and Sehic, O. and Wild, C. (2021): ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies. AIHTA Policy Brief 001/ 1. Update.

Ettinger, S. and Wild, C. (2023): CORE-MD Roadmap for Education & Training: Perceived training needs of regulators, notified bodies and clinicians for successful implementation of the EU MDR. AIHTA Policy Brief 000.

Felder-Puig, R. (2007): [The future of clinical studies?]. Österreichische Ärztezeitung (12): pp. 48-49.

Felder-Puig, R. and Mad, P. and Gartlehner, G. (2007): [Diagnostic studies]. WMW: Wiener Medizinische Wochenschrift 2007. (In Press)

Fried, A. and Wild, C. (2016): Involvement of Citizens and Patients in HTA-Processes – International Experiences and Good Practice Examples. HTA-Projektbericht 86.

Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.

Gartlehner, G. (2009): [Internal manual. Part 2 (2nd Ed.)]. HTA-Projektbericht 06.

Gartlehner, G. and Wild, C. and Mad, P. (2008): [Systematic reviews and meta-analyses]. WMW: Wiener Medizinische Wochenschrift 158 (3-4): pp. 127-133.

Geiger-Gritsch, S. and Absenger, G. and Endel, F. and Flicker, M. and Hermann, A. and Kocher, F. and Olschewski, H. and Pall, G. and Wurm, M. and Zechmeister, M. (2021): Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice. A Pilot Project in Cooperation with Tirol Kliniken GmbH & KAGes. HTA-Projektbericht 126.

Gerdvilaite, J. and Nachtnebel, A. (2011): Disinvestment. Overview of disinvestment experiences and challenges in selected countries. HTA-Projektbericht 57.

Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.

Glanz, K.A. (2021): Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with Real World Evidence (RWE). HTA-Projektbericht 140.

Gregor-Patera, N. and Schader , M. and Wild, C. (2016): Non-interventional studies (NIS) in Austria. A systematic analysis. Rapid Assessment 007c.

Gregor-Patera, N. and Wild, C. (2017): Research interests of Non-interventional studies (NIS) in Austria. Update of the systematic analysis. Rapid Rapid Assessment 007c. Update 2017.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Guba, B. (2008): [Systematic literature search]. WMW: Wiener Medizinische Wochenschrift 158 (01-02): pp. 62-69.

Hintringer, K. (2012): Quality Appraisal of Written Consumer Health Information for Patients with Chronic Myeloid Leukaemia (CML) . HTA-Projektbericht 52.

Huic, M. and Goetz, G. (2023): Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques. HTA-Projektbericht 156.

Jeindl, R. and Goetz, G. (2021): Process and evaluation of digital health applications in the context of "symptom-checkers". HTA-Projektbericht 141.

Kirisits, A. and Wild, C. (2012): Efficacy of Hyperthermia Treatment in combination with radio- or chemotherapy in Breast-, Bladder-, Cervix Carcinoma and Soft Tissue Sarcoma patients. Update 2012. Decision Support Document 36 / Update 2012.

Kisser, A. and Mayer, J. and Wild, C. (2014): Opportunities and strategies to drive appropriate use of MRI in Austria. HTA-Projektbericht 80.

Kisser, A. and Naimer, Ch. (2015): Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2. HTA-Projektbericht 80b.

Kisser, A. and Zechmeister-Koss, I. (2014): Procedural guidance for the systematic evaluation of biomarker tests. Decision Support Document 77.

Krüger, L.J. and Wild, C. (2013): Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: An analysis of seven high-risk medical devices. HTA-Projektbericht 73.

Mad, P. and Felder-Puig, R. and Gartlehner, G. (2007): [Randomized controlled trials]. WMW: Wiener Medizinische Wochenschrift April 2007. (In Press)

Mathis, S. and Wild, C. (2008): [Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies]. HTA-Projektbericht 11.

Mathis, S. and Gartlehner, G. (2008): [Cohort studies]. WMW: Wiener Medizinische Wochenschrift 158 (05-06): pp. 174-179.

Mayer, J. and Nachtnebel, A. (2013): Identification of ineffective interventions and technologies: Existing models and their implementation. HTA-Projektbericht 68.

Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.

Patera, N. (2011): Quality of care in oncology and its measurement. HTA-Projektbericht 49a.

Patera, N. (2011): Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research. HTA-Projektbericht 48.

Patera, N. and Wild, C. (2014): Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations. Decision Support Document 72.

Patera, N. and Wild, C. (2012): Generic indicators for process quality in oncological care: A compendium. HTA-Projektbericht 49b.

Piso, B. and Tüchler, H. (2012): Outpatient cardiac rehabilitation. Part V: Study protocol "Multi-centre, prospective cohort study with two control groups (with/without phase III)". Decision Support Document 50.

Piso, B. and Tüchler, H. (2011): Outpatient cardiac rehabilitation part IV: Options for a prospective study. Decision Support Document 048.

Puig, S. and Felder-Puig, R. (2006): [Evidence-based radiology: A new approach to evaluate the clinical practice of radiology]. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 178 (7): pp. 671-679.

Radlberger, P. and Zechmeister, I. (2011): IFEDH - Innovative Framework for Evidence-based Decisionmaking in Health Care – Standardised working in HTA (WP 1.2). HTA-Projektbericht 044a.

Reinsperger, I. and Piso, B. (2014): Re-orientation of the Austrian parent-child preventive care programme, part X: further development of the mother-child-pass.. Decision Support Document 78.

Reinsperger, I. and Rosian, K. and Winkler, R. and Piso, B. (2018): Re-orientation of the Austrian parent-child preventive care programme. Part XI: Further development of the mother-child-pass: Screening recommendations of the expert working group for pregnancy, puerperium and early childhood (0-6 years). HTA-Projektbericht 92.

Reinsperger, I. and Winkler, R. and Piso, B. (2013): Re-orientation of the Austrian parent-child preventive care programme. Part IX: Recommendations from evidence-based guidelines for screening measures during pregnancy and early childhood (0-6 yrs.) . HTA-Projektbericht 62.

Rummel, P. and Hawlik, K. and Wild, C. (2016): Health Technology Assessments on Medical Devices in Europe. Rapid Assessment 012.

Schimetta, W. (2005): [Non-interventional, observational studies of drugs. Editorial]. HTA-Newsletter 39: pp. 1-2.

Sehic, O. and Wild, C. (2022): CAR-T Cell-Therapies in Development, Update 2022. AIHTA Policy Brief 006a/ 1. Update.

Sehic, O. and Wild, C. (2021): Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017. AIHTA Policy Brief 010.

Semlitsch, T. and Horvath, K. (2019): Screening for Diabetes mellitus: guideline recommendations. HTA-Projektbericht 118.

Stanak, M. and Strohmaier, C. (2019): Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review. HTA-Projektbericht 125.

Warmuth, M. and Stumpner, T. (2012): Therapeutic hypothermia (TH). Decision Support Document 63.

Wild, C and Wolf, S and Goetz, G and Walter, M and McEntee, J and Stanak, M and Ettinger, S and Strohmaier, C and Erdos, J and Huić, M (2020): Covid-19: HSS/ Horizon Scanning Living Document. AIHTA Policy Brief 002.

Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.

Wild, C. and Sehic, O. (2020): Proton and carbon ion therapy - an update on indications. AIHTA Policy Brief 004.

Wild, C. (2007): [External manual. Part 1]. HTA-Projektbericht 03.

Wild, C. (2005): [6th Annual Meeting of the German Network for Evidence Based Medicine. Workshop: Bias spotting. Editorial]. HTA-Newsletter 35: p. 1.

Wild, C. (2005): [Case series studies]. HTA-Newsletter 35: p. 2.

Wild, C. (2005): [Methods for meta-analyses of diagnostic accuracy studies]. HTA-Newsletter 35: pp. 2-3.

Wild, C. (2005): [Randomised versus non-randomised studies] . HTA-Newsletter 35: p. 4.

Wild, C. (2005): [Measuring patient-based outcomes]. HTA-Newsletter 35: pp. 3-4.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics]. ITA-Newsletter September 2004: p. 13.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics. Editorial]. HTA-Newsletter 28: p. 1.

Wild, C. (2001): [Limits of the evidence-based medicine: Conflicts of interests]. ITA-Newsletter December 2001: p. 10.

Wild, C. (2001): [Limitations of evidence based medicine. Editorial]. HTA-Newsletter 01: p. 1.

Wild, C. and Goldgruber, R. (2004): [Non-commercial clinical trials]. ITA-Newsletter March 2004: pp. 10-11.

Wild, C. and Jonas, S. (2000): [Symposium "Evidence-based Medicine"]. ITA-Newsletter December 2000: pp. 8-9.

Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.

Wild, C. (2015): Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report. Decision Support Document 88.

Wild, C. (2012): Avastin for Age-related Macular-Degeneration. Evidence synthesis after CATT, IVAN, MANTA. Rapid Assessment 005.

Wild, C. (2001): [Evidence-based medicine: Continuing education for diabetologists].

Wild, C. (2001): [Assessing medical interventions]. ManagMed (3).

Wild, C. and Gartlehner, G. (2007): [Health technology assessment]. WMW: Wiener Medizinische Wochenschrift 2007. (Submitted)

Wild, C. and Gregor-Patera, N. (2015): HTA-Strategy for Lithuania. Decision Support Document 90a.

Wild, C. and Gregor-Patera, N. and Stricka, M. and Karnickas, L. (2015): Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices. Decision Support Document 90.

Wild, C. and Hintringer, K. and Narath, M. (2013): Hadron therapy: Proton and carbon ion therapy - A review of clinical evidence of efficacy, ongoing research and reimbursement. HTA-Projektbericht 74.

Wild, C. and Patera, N. and Küllinger, R. and Narath, M. (2015): PET/PET-CT Evidence for need based planning (in oncology indications). HTA-Projektbericht 77.

Wild, C. and Schimetta, W. (2005): [Application studies]. ITA-Newsletter December 2005: pp. 5-6.

Wohlhöfner, K. (2021): (Good) practice organisational models using real-world evidence for public funding of high prized therapies. HTA-Projektbericht 138.

Wolf, S. and Erdos, J (2021): Epidemiology of long COVID: a preliminary report. German short version of the original KCE report. HTA-Projektbericht 135a.

Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. German version. Decision Support Document 43.

Zechmeister, I. and Huić, M. (2011): Vascular-Endothelial-Growth-Factor-Inhibitors (anti-VEGF) in the Management of Diabetic Macular Oedema. English version. Decision Support Document 43.

Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.

Zechmeister-Koss, I. (2012): Standards on how to parameterise models via published literature: Input of the LBI-HTA for IFEDH work package 4. HTA- Projektbericht 58.